Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real‐World Analysis of Donor‐Derived Cell‐Free DNA‐Based Surveillance Protocol
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15481 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Leor Akabas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, Morgan Stanley Children's Hospital of New York-Presbyterian…. Hauptthemen laut MEDLINE: Graft Rejection, Heart Transplantation, Cell-Free Nucleic Acids, Tissue Donors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Purpose
Acute cellular (ACR) and antibody‐mediated (AMR) rejection are risk factors for allograft loss in heart transplant (HT) recipients. Endomyocardial biopsy (EMB), although considered the gold standard for rejection surveillance, is invasive and has high interobserver variability. Noninvasive donor‐derived cell‐free DNA (dd‐cfDNA) sampling has a high negative predictive value (NPV) for rejection in adults and is increasingly used in pediatrics. This single center study aimed to test the performance of dd‐cfDNA in screening for acute rejection (AR) and donor‐specific antibodies (DSAs) in pediatric HT recipients.
Methods
Blood samples for dd‐cfDNA were obtained per clinical protocol for all eligible HT recipients in our center from July 1, 2022 to December 31, 2023. Primary endpoints were episodes of AR, pathology grading of EMBs temporally related to ddcfDNA sampling (0–150 days), and presence of DSAs.
Results
There were 471 interpretable samples, in 192 unique patients. Of those, 199 dd‐cfDNA tests were paired with EMB ± DSA in 152 patients. Abnormal dd‐cfDNA (> 0.2%) was found in 77 samples (median 0.48%, range 0.21%–11%) and led to EMB, where one sample was positive for ACR (grade 2R), 13 for AMR, yielding an NPV of 97% for AMR. After excluding abnormal ddcfDNA testing associated with AR, 65 abnormal dd‐cfDNA tests were paired with DSA testing. The NPV of the test for detection of DSAs was 93%.
Conclusion
Implementation of noninvasive rejection surveillance with dd‐cfDNA in a pediatric cohort demonstrates high NPV for AR and high DSAs, making it an ideal screening tool for long‐term monitoring of allograft health in pediatrics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, USA.
- Division of Pediatric Cardiology, Columbia University Vagelos College of Physicians and Surgeons, Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, USA.
- Pediatric Cardiovascular Clinical Research Core, Pediatric Heart Center, Columbia University Vagelos College of Physicians and Surgeons, Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, U…
ORCID-Profile: Yun Zhang, Irene D Lytrivi
Zitieren
APA
Akabas, L., Bravo, S. A., Zhang, Y., Simonelli, A., Zuckerman, W. A., Richmond, M. E., & Lytrivi, I. D. (2024). Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real‐World Analysis of Donor‐Derived Cell‐Free DNA‐Based Surveillance Protocol. Clinical Transplantation. https://doi.org/10.1111/ctr.15481
Vancouver
Akabas L, Bravo SA, Zhang Y, Simonelli A, Zuckerman WA, Richmond ME, et al. Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real‐World Analysis of Donor‐Derived Cell‐Free DNA‐Based Surveillance Protocol. Clinical Transplantation. 2024. doi:10.1111/ctr.15481
BibTeX
@article{Akabas2024,
author = {Akabas, Leor and Bravo, Stephen A and Zhang, Yun and Simonelli, Anna and Zuckerman, Warren A and Richmond, Marc E and Lytrivi, Irene D},
title = {Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real‐World Analysis of Donor‐Derived Cell‐Free DNA‐Based Surveillance Protocol},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15481}
}
EUVIMED